EFFECT OF E.COLI PHAGE LYSATE VACCINATIONS ON IL-12 ANDIFN-ΓSECRETION AND PARAMETERS OF CANCER GROWTH IN LAB MICE WITH EHRLICH CARCINOMA
Аннотация
Anticancer treatment effects of E.coli phage lysate vaccinations (0,25 ml, 1x intraperitoneally, with 5 days interval) have been studied in 2-3 months old 30 lab. mice with Ehrlich carcinoma. The treatment efficacy was estimated by the dynamic of growth of cancer tissue and cancer growth inhibition percent. Immune status was studied by measurement of IL-12 and IFN-γ concentration using ELISA. Investigations have shown that E.coli phage lysate injections delay the cancer growth. Anticancer treatment effect was especially obvious and well expressed in case of 3and 4times vaccinations. During the same period increased secretion of IL-12 and IFN-γ in treated mice compared to the untreated and healthy control was detected. After 5-8 injections the anticancer action of the preparation decreased. Prolonged vaccinations supported progressive cancer growth. Concentration of IL-12 and IFN-γwas decreased as well. The peak of cytokines’ secretion was reached after 3-timesadministration of phagelysate, but after 5-8 vaccinations there were no statistically significant difference between results of experimental and control group animals. Could be concluded that the bacterial preparation - E.coli phage lysate reveal anticancer immunomodulatory properties. For positive treatment results the detection of optimal dosage and regimen of vaccinations is important.
Скачивания
Библиографические ссылки
Bradford M. - Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding//Anal. Biochem., 1976, #72:248-254.
Cavallo F. et al. - Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic IL-12// Cancer Res., 1999, #59, 414-421.
Gambashidze, K. G., Kalandarishvili, K. G., Khorava, P. A., Azaladze, T. N., Lasareishvili, B. G., Dzhaiani, E. G., & Tediashvili, M. I. [Application of bacterial thermo-and phagelysates for suppression of malignant tumor growth in experimental studies: 1. Anticancer efficacy of thermo- and phagelysates of E.coli]. Georgian Medical News. 2012 Jan(202):42-47. PMID: 22392782.
HiscoxS., Jiang W. - Interleukin-12, an emerging anti-tumour cytokine//In Vivo, 1997, #1, 125-132.
Huang B. et al. - Toll-like receptors on tumor cells facilitate evasion of immune surveillance// Cancer Res., 2005, #65( 12), 5009-5014.
Huang B. et al. - Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling//Cancer Res., 2007, #67(9), 4346-4352.
Iwasaki A., Medzhitov R. - Toll-like receptor control of the adaptive immune responses// Natl. Immunol., 2004, #5( 10), 987-995.
Krieg A. - Development of TLR9 agonists for cancer therapy// J. Clin. Invest.,2007, # 117(5), 1184-1194.
Lee S. etal.-The regulation and biological activity of interleukin 12// Leuk Lymphoma, 1998, #29,427- 438.
Ngai P. et al. - Gamma interferon responses of CD4 and CD8 T-cell subsets are quantitatively different and independent of each other during pulmonary Mycobacterium bovis BCG infection// Infect. Immun., 2007, #75(5), 2244-2252.
Pasare C., Medzhitov R. - Toll-like receptors: linking innate and adaptive immunity// Adv. Exp. Med. Biol., 2005, #560, 11-18.
Shcheblyakov D. et al. — Toll-like receptors (TLRs): The role in tumor progression//Acta Naturae, 2010, #2(3), 21-29.
Shirota H., Klinman D. - Recent progress concerning CpG DNA and its use as a vaccine adjuvant// Expert Rev. Vaccines, 2014, #13,299-312.
Stockfleth E. et al. -The use ofToll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview// Br. J. Dermatol., 2003, #149, Suppl. 66, 53-56.
Sun Y. etal.- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and first clinical phase 1 study// Gene Ther., 1998, #5,481 -490.
T utemeyer S. et al. - IFN-gamma enhances production of nitric oxide from macrophages via a mechanism that depends on nucleotide oligomerization domain-2//J. Immunol., 2006, U176(8), 4804-4810.
Yang Z. et al. - IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma//J. Clin. Invest., 2012, #122(4), 1271-1282.
Dalpke A. et al. - Activation of Toll-Like Receptor 9 by DNA from Different Bacterial Species// Infection and Immunity, 2006, #74(2), 940-946.
